Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, which will be presented at the Society for Investigative Dermatology 2025 Annual Meeting [1][2] - The company will discuss this data during its first quarter 2025 business update conference call scheduled for May 8, 2025 [1][3] Presentation Details - The presentation titled "Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action" will be delivered by Dr. Albert S. Chiou [2] - The poster presentation is set for May 8, 2025, from 4:30 – 6:00 pm PT, while the oral presentation will occur on May 10, 2025, from 9:50 – 10:00 am PT [2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [4] - The lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK, with other candidates in development for different cancer indications [4]

Core Insights - Corvus Pharmaceuticals has appointed Richard van den Broek to its board of directors, bringing over 30 years of experience in the life sciences industry [1][2] - The company is focused on advancing ITK inhibition as a novel approach to immunotherapy for various cancers and immune diseases [3] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing ITK inhibition, with its lead product candidate being soquelitinib, an investigational oral small molecule drug [3] - The company is also working on other clinical-stage candidates targeting a range of cancer indications [3] Leadership Experience - Richard van den Broek has a strong background in biotechnology, having previously served on the board of Pharmacyclics, where he contributed to the development of the first BTK inhibitor for lymphomas and immune diseases [2] - He is currently the managing partner at HSMR Advisors and has held directorships at Pulse Biosciences and Cogstate [2]

Corvus Pharmaceuticals (NASDAQ: CRVS ) is essentially a biopharmaceutical company that develops treatments for autoimmune conditions and cancer. Their leading candidate is Soquelitinib, an ITK inhibitor with anti-inflammatory and anti-tumor properties. Soquelitinib can be used forMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, ...

Over the last nine months since we last took a look at them, plucky little startup pharma Corvus Pharmaceuticals (NASDAQ: CRVS ) has been plugging along, releasing fresh rounds of data, business and clinical, that sent theHello! We're Derek and Betsy, a husband-and-wife investment duo. Our experiences include academia, fintech, software engineering, manufacturing and corporate finance. We're value investors who know our circle of competence and have a healthy appreciation for macroeconomic trends. We're als ...

Financial Data and Key Metrics Changes - Research and development (R&D) expenses in Q4 2024 were $5.2 million, up from $3.2 million in Q4 2023, primarily due to increased clinical trial expenses for socalitinib [6] - Full year R&D expenses for 2024 totaled $19.4 million, compared to $16.5 million in 2023, reflecting an increase of approximately $2.9 million [7] - The net loss for Q4 2024 was $12.1 million, compared to a net loss of $6.7 million in Q4 2023 [8] - Total stock compensation expense for Q4 2024 was $0.8 million, compared to $0.6 million in Q4 2023 [8] - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $52 million, up from $27.1 million at the end of 2023 [9] Business Line Data and Key Metrics Changes - Socalitinib showed a 39% objective response rate in the Phase 1 trial for relapsed T-cell lymphoma, with a 26% complete response rate, significantly higher than standard chemotherapies [12] - Interim data from the Phase 1 trial of socalitinib in moderate to severe atopic dermatitis indicated significant responses compared to placebo [13] Market Data and Key Metrics Changes - The company is enrolling a registrational Phase 3 trial of socalitinib in patients with relapsed peripheral T-cell lymphoma [12] - The Phase 1 trial for atopic dermatitis includes four cohorts, with a total of 16 subjects each, showing promising efficacy results [15][19] Company Strategy and Development Direction - The company aims to position socalitinib as a first-in-class oral therapy for immune diseases and cancer, leveraging its unique mechanism of action [11] - Plans include advancing multiple clinical trials for socalitinib, including a Phase 2 trial in solid tumors and a Phase 2 trial in atopic dermatitis [29][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of socalitinib, citing a strong body of evidence from clinical and preclinical research [11] - The company anticipates its cash runway will extend into the first quarter of 2026, allowing for the execution of key milestones [10][33] Other Important Information - The company is also advancing other clinical stage development programs, including adenosine A2A receptor antagonists for cancer treatment [30] - The ALPS trial is being conducted under a clinical research agreement with the NIH, targeting a rare autoimmune disease with a patient population of approximately 2,500 in the U.S. [68] Q&A Session Summary Question: Will the May update include full data on cohorts three and additional patients on cohort two? - Management confirmed that the May meeting will report full datasets on cohorts one, two, and three, including biomarker data [38] Question: What efficacy hurdles are being considered for the Phase 2a trial? - Management indicated satisfaction with the efficacy seen in cohorts one and two, noting a significant difference compared to placebo [41][44] Question: What are the plans for cohort four and the rationale for dosing? - Management stated that cohort four is planned at a 400 mg dose, pending review of cohort three data [50][52] Question: What is the addressable patient population for the ALPS indication? - Management noted approximately 2,500 patients in the U.S. with ALPS, emphasizing the potential for long-term treatment [68] Question: What subpopulations are being targeted in the upcoming Phase 2 for atopic dermatitis? - Management indicated that the focus will be on patients with moderate to severe atopic dermatitis who have failed prior treatments [76]

Corvus Pharmaceuticals (CRVS) Q4 2024 Earnings Call March 26, 2025 12:20 AM ET Company Participants Zack Kubow - Managing DirectorLeiv Lea - Chief Financial OfficerRichard Miller - Co-Founder, President, CEO & Chairman of the BoardCha Cha Yang - Senior Associate, Biotech Equity ResearchSean Lee - VP - Equity Research Conference Call Participants Jeff Jones - Managing Director - Senior AnalystDaniel Browder - Analyst Operator Good afternoon, everyone. Thank you for standing by, and welcome to the Corvus Phar ...

Corvus Pharmaceuticals, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commission Fil ...

Financial Performance - The net loss for Q4 2024 was $12.1 million, compared to a net loss of $6.7 million for the same period in 2023[13]. - Corvus Pharmaceuticals reported a net loss of $12.1 million for Q4 2024, compared to a net loss of $6.7 million in Q4 2023, reflecting an increase of 81.5% year-over-year[28]. - Total operating expenses for the year ended December 31, 2024, were $27.5 million, up from $23.4 million in 2023, representing a 17.9% increase[27]. - The net loss per share for the year ended December 31, 2024, was $1.02, compared to $0.56 in 2023, reflecting a significant increase in losses per share[28]. - The company reported a change in fair value of warrant liability amounting to a loss of $33.4 million for the year ended December 31, 2024[28]. Cash and Funding - Corvus Pharmaceuticals reported cash, cash equivalents, and marketable securities of $52.0 million as of December 31, 2024, up from $27.1 million as of December 31, 2023[10]. - Cash, cash equivalents, and marketable securities increased to $52.0 million as of December 31, 2024, from $27.1 million in 2023, showing a growth of 91.7%[30]. - The company completed a registered direct offering generating $30.3 million in net proceeds during 2024[11]. - Corvus expects its cash to fund operations into the first quarter of 2026 based on current plans[11]. - The company anticipates funding operations into the first quarter of 2026, with ongoing clinical trials and product development milestones[25]. Research and Development - Research and development expenses for the full year 2024 totaled $19.4 million, an increase from $16.5 million in 2023, primarily due to higher clinical trial costs associated with soquelitinib[12]. - Research and development expenses for Q4 2024 were $6.0 million, compared to $4.0 million in Q4 2023, indicating a 49.3% increase[27]. - In the Phase 1 clinical trial for atopic dermatitis, 26% of patients in the soquelitinib group achieved IGA 0 or 1, and 37% achieved EASI 75, compared to none in the placebo group[4]. - The Phase 3 clinical trial for soquelitinib in relapsed peripheral T cell lymphoma (PTCL) is enrolling a total of 150 patients, with the primary endpoint being progression-free survival[10]. - Corvus initiated a Phase 2 clinical trial for autoimmune lymphoproliferative syndrome (ALPS) with an anticipated enrollment of up to 30 patients, focusing on efficacy determined by reductions in splenomegaly and lymph node volumes[6]. - The Phase 1b/2 clinical trial for ciforadenant in metastatic renal cell cancer is fully enrolled with 60 patients, evaluating deep response rate as the efficacy endpoint[10]. - Mupadolimab is being studied in combination with pembrolizumab in a Phase 1b/2 clinical trial for advanced head and neck cancers and NSCLC patients[23]. - Corvus plans to announce additional results from the atopic dermatitis trial, including data from all cohorts, in May 2025[4]. Corporate Governance - The company has a 49.7% equity stake in Angel Pharmaceuticals, which is developing three clinical-stage candidates in Greater China[24]. - Corvus Pharmaceuticals has designated three individuals on Angel Pharmaceuticals' five-person Board of Directors, indicating strong governance collaboration[24].

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus ...

Core Insights - Corvus Pharmaceuticals announced additional data from its Phase 1/1b clinical trial of soquelitinib for T cell lymphoma, showcasing strong anti-tumor activity and encouraging results compared to standard treatments [1][2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a new immunotherapy approach for various cancers and immune diseases [10] - The lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [10] Clinical Trial Data - The Phase 1/1b trial enrolled 25 patients, with 23 evaluable patients showing a 39% objective response rate, including a 26% complete response rate [4][6] - The median duration of response was 17.2 months, with a median progression-free survival (PFS) of 6.2 months and an 18-month PFS rate of 30%, significantly better than the <20% rate for standard treatments [6] - Soquelitinib was well-tolerated, with no new safety signals or dose reductions reported [6] Future Trials - A registrational Phase 3 trial is underway for soquelitinib in patients with relapsed Peripheral T cell lymphoma (PTCL), aiming to enroll 150 patients [4] - The trial will compare soquelitinib against physician's choice of either belinostat or pralatrexate, with the primary endpoint being PFS [4] Mechanism of Action - Soquelitinib is designed to selectively inhibit ITK, which plays a crucial role in T cell immune function, potentially enhancing anti-tumor immunity by reducing T cell exhaustion [9] - The drug has shown the ability to shift T cell differentiation towards Th1 helper cells, which are essential for tumor immunity [9] Industry Context - Peripheral T cell lymphoma (PTCL) accounts for about 10% of non-Hodgkin's lymphomas in Western populations, with a high relapse rate and poor outcomes for patients [7] - There are currently no FDA-approved treatments for relapsed PTCL based on randomized trials, highlighting a significant unmet medical need [4][7]